Quarterly Drug Approvals: January 2026

Generic name	Brand name	Manufacturer	Indication(s)	Route of administration	Month approved*
aficamten	Myqorzo	Cytokinetics	Obstructive hypertrophic cardiomyopathy	Oral	December
depemokimab-ulaa	Exdensur	GlaxoSmithKline	Severe eosinophilic asthma (≥ 12 years of age)	SC	December
fibrinogen, human-chmt	Fesilty	Grifols	Congenital fibrinogen deficiency (pediatrics from birth and adults)	IV	December
mitapivat	Aqvesme	Agios	Anemia in alpha- or beta-thalassemia	Oral	December
narsoplimab-wuug	Yartemlea	Omeros	HSCT-associated thrombotic microangiopathy (≥ 2 years of age)	IV	December
trofinetide powder for oral solution	Daybue Stix	Acadia	Rett syndrome (≥ 2 years of age)	Oral	December
doxecitine and doxribtimine	Kygevvi	UCB	Thymidine kinase 2 deficiency (symptom onset on or before 12 years of age)	Oral	November
plozasiran	Redemplo	Arrowhead	Familial chylomicronemia syndrome	SC	November
sibeprenlimab-szsi	Voyxact	Otsuka	Primary IgA nephropathy	SC	November
nerandomilast	Jascayd	Boehringer Ingelheim	Idiopathic pulmonary fibrosis	Oral	October
elamipretide	Forzinity	Stealth	Barth syndrome (adults and pediatrics weighing ≥ 30 kg)	SC	September
immune globulin intravenous, human-kthm	Qivigy	Kedrion	Primary humoral immunodeficiency	IV	September
paltusotine	Palsonify	Crinetics	Acromegaly	Oral	September
remibrutinib	Rhapsido	Novartis	Chronic spontaneous urticaria	Oral	September
apremilast ER tablets	Otezla XR	Amgen	(1) PsA (≥ 6 years of age weighing ≥ 50 kg); (2) PsO (≥ 6 years of age weighing ≥ 50 kg); (3) Oral ulcers associated with Behçet's disease (adults)	Oral	August
brensocatib	Brinsupri	Insmed	Non-cystic fibrosis bronchiectasis (≥ 12 years of age)	Oral	August
donidalorsen	Dawnzera	Ionis	Hereditary angioedema prophylaxis (≥ 12 years of age)	SC	August
lecanemab-irmb	Leqembi Iqlik	Eisai	Alzheimer's disease	SC	August
rilzabrutinib	Wayrilz	Genzyme	Persistent or chronic immune thrombocytopenia	Oral	August
sebetralstat	Ekterly	Kalvista	Acute attacks of hereditary angioedema (≥ 12 years of age)	Oral	July
sepiapterin	Sephience	PTC Therapeutics	Phenylketonuria (≥ 1 month of age)	Oral	July
clesrovimab-cfor	Enflonsia	Merck	RSV LRTD prevention (neonates and infants)	IM	June
garadacimab-gxii	Andembry	CSL Behring	Hereditary angioedema prophylaxis (≥ 12 years of age)	SC	June
immune globulin infusion (human) 10% solution	Gammagard Liquid ERC	Takeda	Primary humoral immunodeficiency (≥ 2 years of age)	IV, SC	June
lenacapavir oral tablet and SC injection	Yeztugo	Gilead	HIV-1 PrEP (patients weighing ≥ 35 kg)	Oral, SC	June
nitisinone oral tablet	Harliku	Cycle	Alkaptonuria	Oral	June
hydrocortisone oral solution	Khindivi	Eton	Adrenocortical insufficiency (≥ 5 years of age)	Oral	May
treprostinil inhalation powder	Yutrepia	Liquidia	Improve exercise ability in patients with: (1) PAH; (2) pulmonary hypertension associated with interstitial lung disease	Oral inhalation	May
atrasentan	Vanrafia	Novartis	Primary IgA nephropathy	Oral	April
nipocalimab-aahu	Imaavy	Janssen	Generalized myasthenia gravis in patients ≥ 12 years of age who are anti-AChR or anti-MuSK antibody positive	IV	April
diazoxide choline	Vykat XR	Soleno	Hyperphagia in Prader-Willi syndrome (≥ 4 years of age)	Oral	March
fitusiran	Qfitlia	Sanofi	Bleed prophylaxis in hemophilia A or B with or without inhibitors (≥ 12 years of age)	SC	March
tesamorelin F8 formulation	Egrifta WR	Theratechnologies	HIV lipodystrophy	SC	March
apomorphine HCl	Onapgo	Supernus	Advanced Parkinson's disease	SC (continuous infusion)	February
chenodiol	Ctexli	Mirum	Cerebrotendinous xanthomatosis	Oral	February

Generic name	Brand name	Manufacturer	Indication(s)	Route of administration	Month approved*
berotralstat oral pellets	Orladeyo	Biocryst	Hereditary angioedema prophylaxis (2 to < 12 years of age)	Oral	December
caplacizumab-yhdp	Cablivi	Ablynx	Indication for acquired thrombotic thrombocytopenic purpura expanded to include patients ≥ 12 years of age	IV, SC	December
inebilizumab-cdon	Uplizna	Amgen	Generalized myasthenia gravis in AChR or MuSK antibody positive patients	IV	December
nerandomilast	Jascayd	Boehringer Ingelheim	Progressive pulmonary fibrosis	Oral	December
aflibercept	Eylea HD	Regeneron	Macular edema following RVO	Intravitreal	November
golimumab	Simponi	Janssen	Indication for ulcerative colitis expanded to include pediatrics weighing ≥ 15 kg	SC	October
obinutuzumab	Gazyva	Genentech	Active lupus nephritis	IV	October
sodium phenylbutyrate	Olpruva	Acer	Indication for urea cycle disorders expanded to include patients ≥ 1 year of age weighing ≥ 7 kg	Oral	October
sotatercept-csrk	Winrevair	Merck	Indication for PAH now specifies reduced risk of hospitalization, lung transplantation and death	SC	October
tezepelumab-ekko	Tezspire	AstraZeneca	Chronic rhinosinusitis with nasal polyps (≥ 12 years of age)	SC	October
tofacitinib	Xeljanz	Pfizer	Indication for PsA expanded to include patients ≥ 2 years of age (IR tablets and oral solution only)	Oral	October
evinacumab-dgnb	Evkeeza	Regeneron	Indication for HoFH expanded to include patients ≥ 1 year of age	IV	September
guselkumab	Tremfya	Janssen	Indications for PsO and PsA expanded to include patients ≥ 6 years of age weighing ≥ 40 kg	SC	September
von Willebrand factor, recombinant	Vonvendi	Takeda	Expanded indications: (1) bleeding prophylaxis in all types of von Willebrand disease (VWD); (2) on-demand and perioperative use in pediatric patients with VWD	IV	September
tocilizumab	Actemra	Genentech	Indication for COVID-19 in hospitalized patients expanded to include patients ≥ 2 years of age	IV	August
apremilast	Otezla	Amgen	Indication for PsA expanded to include patients ≥ 6 years of age weighing ≥ 20 kg	Oral	July
avatrombopag	Doptelet	Sobi	Indication expanded to include patients ≥ 1 year of age with persistent or chronic immune thrombocytopenia	Oral	July
bedaquiline	Sirturo	Janssen	Indication for pulmonary tuberculosis expanded to include patients ≥ 2 years of age weighing ≥ 8 kg	Oral	July
concizumab-mtci	Alhemo	Novo Nordisk	Indication expanded to include bleeding prophylaxis in hemophilia A or B without inhibitors (≥ 12 years of age)	SC	July
lonapegsomatropin-tcgd	Skytrofa	Ascendis	Growth hormone deficiency in adults	SC	July
pegcetacoplan	Empaveli	Apellis	C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis (≥ 12 years of age)	SC	July
belimumab	Benlysta	GlaxoSmithKline	Autoinjector approved for pediatric patients ≥ 5 years of age with lupus nephritis	SC	June
dupilumab	Dupixent	Regeneron	Bullous pemphigoid	SC	June
emapalumab-lzsg	Gamifant	Novimmune	Expanded indication to include hemophagocytic lymphohistiocytosis/ macrophage activation syndrome in Still's disease (newborn and older)	IV	June
glecaprevir and pibrentasvir	Mavyret	Abbvie	Acute HCV infection (≥ 3 years of age)	Oral	June
antihemophilic factor (recombinant), PEGylated-aucl	Jivi	Bayer	Use expanded to include pediatric patients ≥ 7 years of age with hemophilia A	IV	May
mepolizumab	Nucala	GlaxoSmithKline	COPD with an eosinophilic phenotype	SC	May
ranibizumab	Susvimo	Genentech	Diabetic retinopathy	Intravitreal	May
dupilumab	Dupixent	Regeneron	Chronic spontaneous urticaria (≥ 12 years of age)	SC	April
inebilizumab-cdon	Uplizna	Amgen	IgG4-related disease	IV	April
osilodrostat	Isturisa	Recordati Rare Diseases	Expanded indication for endogenous hypercortisolemia in Cushing's syndrome	Oral	April
upadacitinib	Rinvoq	Abbvie	Giant cell arteritis	Oral	April
fluocinolone acetonide	Iluvien	Ani	Chronic non-infectious uveitis affecting the posterior segment of the eye	Intravitreal	March
furosemide	Furoscix	scPharmaceuticals	Edema in patients with CKD	SC (continuous infusion)	March
guselkumab	Tremfya	Janssen	Crohn's disease	IV, SC	March
iptacopan	Fabhalta	Novartis	Complement 3 glomerulopathy	Oral	March
nedosiran	Rivfloza	Novo Nordisk	Expanded indication (≥ 2 years of age) for primary hyperoxaluria type 1	SC	March
vutrisiran	Amvuttra	Alnylam	Transthyretin amyloid cardiomyopathy (ATTR-CM)	SC	March
eculizumab	Soliris	Alexion	Expanded indication (≥ 6 years of age) for generalized myasthenia gravis	IV	February
ranibizumab	Susvimo	Genentech	Diabetic macular edema	Intravitreal	February
esketamine	Spravato	Janssen	Monotherapy for treatment-resistant depression	Intranasal	January
mirikizumab-mrkz	Omvoh	Eli Lilly	Crohn's disease	IV, SC	January

Generic name	Brand name	Manufacturer	Indication(s)	Route of administration	Month approved*
amivantamab and hyaluronidase-lpuj	Rybrevant Faspro	Janssen	Approved for all of the same indications as IV amivantamab-vmjw (Rybrevant)	SC	December
mosunetuzumab-axgb	Lunsumio Velo	Genentech	R/R follicular lymphoma	SC	December
sevabertinib	Hyrnuo	Bayer	Locally advanced or metastatic non-squamous NSCLC with HER2 (ERBB2) TKD activating mutations	Oral	November
ziftomenib	Komzifti	Kura Oncology	R/R AML with a susceptible NPM1 mutation	Oral	November
belantamab mafodotin-blmf†	Blenrep	GlaxoSmithKline	R/R multiple myeloma in combination with bortezomib and dexamethasone	IV	October
gemcitabine intravesical system	Inlexzo	Janssen	BCG-unresponsive non-muscle invasive bladder cancer with CIS	Intravesical	September
imlunestrant	Inluriyo	Eli Lilly	ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer	Oral	September
pembrolizumab and berahyaluronidase alfa-pmph	Keytruda Qlex	Merck	Solid tumors	SC	September
dordaviprone	Modeyso	Jazz	Recurrent H3 K27M-mutant diffuse midline glioma (≥ 1 year of age)	Oral	August
leuprolide	Camcevi ETM	Foresee	Advanced prostate cancer	SC	August
zongertinib	Hernexeos	Boehringer Ingelheim	Unresectable or metastatic non-squamous NSCLC with HER2 (ERBB2) TKD activating mutations	Oral	August
linvoseltamab-gcpt	Lynozyfic	Regeneron	R/R multiple myeloma in patients who have received ≥ 4 prior lines of therapy	IV	July
sunvozertinib	Zegfrovy	Dizal (Jiangsu)	Locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations	Oral	July
mitomycin intravesical solution	Zusduri	Urogen	Recurrent low-grade intermediate-risk non-muscle invasive bladder cancer	Intravesical	June
taletrectinib	Ibtrozi	Nuvation Bio	Locally advanced or metastatic ROS1+ NSCLC	Oral	June
avutometinib; defactinib	Avmapki Fakzynja Co-Pack	Verastem	KRAS-mutated recurrent low-grade serous ovarian cancer	Oral	May
telisotuzumab vedotin-tllv	Emrelis	Abbvie	Locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression	IV	May
penpulimab-kcqx	no trade name	Akeso	(1) Recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) in combination with cisplatin or carboplatin and gemcitabine; (2) Metastatic non-keratinizing NPC with progression after prior therapy	IV	April
mirdametinib	Gomekli	SpringWorks	Neurofibromatosis type 1-associated plexiform neurofibromas (≥ 2 years of age)	Oral	February
nilotinib d-tartrate	no trade name	Cipla	Newly diagnosed Ph+ CML in chronic phase (CP); (2) CP and accelerated phase Ph+ CML resistant to imatinib	Oral	February
vimseltinib	Romvimza	Deciphera	Symptomatic tenosynovial giant cell tumor	Oral	February
datopotamab deruxtecan-dlnk	Datroway	Daiichi Sankyo	Unresectable or metastatic HR+, HER2- (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer	IV	January
treosulfan	Grafapex	Medexus	Preparative regimen for allogeneic HSCT in combination with fludarabine for patients with AML or MDS (≥ 1 year of age )	IV	January

†Belantamab mafodotin-blmf (Blenrep) is returning to the market after being discontinued in November 2022

Generic name	Brand name	Manufacturer	Indication(s)	Route of administration	Month approved*
fam-trastuzumab deruxtecan-nxki	Enhertu	Daiichi Sankyo	First-line treatment of unresectable or metastatic HER2+ breast cancer in combination with pertuzumab	IV	December
niraparib and abiraterone acetate	Akeega	Janssen	BRCA2-mutated metastatic castration-sensitive prostate cancer in combination with prednisone	Oral	December
pirtobrutinib	Jaypirca	Eli Lilly	R/R CLL/SLL previously treated with a BTK inhibitor	Oral	December
rucaparib	Rubraca	Pharmaand GmbH	Deleterious BRCA-mutated metastatic castration-resistant prostate cancer previously treated with androgen receptor-directed therapy	Oral	December
atezolizumab and hyaluronidase-tqjs	Tecentriq Hybreza	Genentech	Indication for unresectable or metastatic ASPS expanded to include pediatrics ≥ 12 years of age weighing ≥ 40 kg	SC	November
daratumumab and hyaluronidase-fihj	Darzalex Faspro	Janssen	High-risk smoldering multiple myeloma	SC	November
durvalumab	Imfinzi	AstraZeneca	Resectable gastric and GEJ cancer in combination with FLOT (neoadjuvant and adjuvant treatment)	IV	November
enfortumab vedotin-ejfv	Padcev	Astellas	Muscle invasive bladder cancer in combination with Keytruda or Keytruda Qlex for cisplatin-ineligible patients	IV	November
epcoritamab-bysp	Epkinly	Genmab	R/R follicular lymphoma in combination with lenalidomide and rituximab	SC	November
nivolumab and hyaluronidase-nvhy	Opdivo Qvantig	Bristol-Myers Squibb	Indications for melanoma and CRC expanded to include pediatrics ≥ 12 years of age weighing ≥ 30 kg	SC	November
pembrolizumab	Keytruda	Merck Sharp and Dohme	Muscle invasive bladder cancer in combination with Padcev for cisplatin-ineligible patients	IV	November
pembrolizumab and berahyaluronidase alfa-pmph	Keytruda Qlex	Merck Sharp and Dohme	Muscle invasive bladder cancer in combination with Padcev for cisplatin-ineligible patients	SC	November
selumetinib	Koselugo	AstraZeneca	Indication for neurofibromatosis type 1 with plexiform neurofibromas expanded to include adults	Oral	November
atezolizumab	Tecentriq	Genentech	Extensive-stage SCLC in combination with Zepzelca	IV	October
atezolizumab and hyaluronidase-tqjs	Tecentriq Hybreza	Genentech	Extensive-stage SCLC in combination with Zepzelca	SC	October
cemiplimab-rwlc	Libtayo	Regeneron	Adjuvant treatment of CSCC at high risk of recurrence	IV	October
lurbinectedin	Zepzelca	Jazz	Extensive-stage SCLC in combination with Tecentriq or Tecentriq Hybreza	IV	October
nivolumab and hyaluronidase-nvhy	Opdivo Qvantig	Bristol-Myers Squibb	Unresectable or metastatic MSI-H or dMMR CRC	SC	October
pemetrexed	Axtle	Avyxa	Metastatic non-squamous NSCLC with no EGFR or ALK aberrations in combination with Keytruda and platinum chemotherapy	IV	October
revumenib	Revuforj	Syndax	R/R AML with a susceptible NPM1 mutation (≥ 1 year of age)	Oral	October
selumetinib	Koselugo	AstraZeneca	Indication for neurofibromatosis type 1 with plexiform neurofibromas expanded to include patients ≥ 1 year of age	Oral	September
dasatinib	Phyrago	Handa/Cycle	Patients ≥ 1 year of age with: (1) Ph+ CML in chronic phase; (2) newly diagnosed Ph+ ALL in combination with chemotherapy	Oral	August
darolutamide	Nubeqa	Bayer	Metastatic castration-sensitive prostate cancer as a single agent	Oral	June
datopotamab deruxtecan-dlnk	Datroway	Daiichi Sankyo	Locally advanced or metastatic EGFR-mutated NSCLC	IV	June
pembrolizumab	Keytruda	Merck Sharp and Dohme	Resectable locally advanced head and neck squamous cell carcinoma with tumors expressing PD-L1	IV	June
tafasitamab-cxix	Monjuvi	Incyte	R/R follicular lymphoma in combination with lenalidomide and rituximab	IV	June
belzutifan	Welireg	Merck Sharp and Dohme	Locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma (≥ 12 years of age)	Oral	May
retifanlimab-dlwr	Zynyz	Incyte	(1) Locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) in combination with carboplatin and paclitaxel; (2) Locally recurrent or metastatic SCAC with disease progression as a single agent	IV	May
ipilimumab	Yervoy	Bristol-Myers Squibb	Indication for MSI-H or dMMR CRC in combination with Opdivo expanded to include treatment-naïve patients (≥ 12 years of age)	IV	April
ipilimumab	Yervoy	Bristol-Myers Squibb	Indication for unresectable or metastatic HCC in combination with Opdivo expanded to include treatment-naïve patients	IV	April
nivolumab	Opdivo	Bristol-Myers Squibb	Indication for MSI-H or dMMR CRC in combination with Yervoy expanded to include treatment-naïve patients (≥ 12 years of age)	IV	April
nivolumab	Opdivo	Bristol-Myers Squibb	Indication for unresectable or metastatic HCC in combination with Yervoy expanded to include treatment-naïve patients	IV	April
palbociclib	Ibrance	Pfizer	PIK3CA-mutated, HR+, HER2- locally advanced or metastatic breast cancer in combination with Itovebi and Faslodex	Oral	April
cabozantinib	Cabometyx	Exelixis	Pancreatic and extra-pancreatic neuroendocrine tumors (≥ 12 years of age)	Oral	March
durvalumab	Imfinzi	AstraZeneca	Neoadjuvant and adjuvant treatment for muscle invasive bladder cancer	IV	March
tislelizumab-jsgr	Tevimbra	BeiGene	First line for advanced esophageal squamous cell carcinoma in combination with platinum-containing chemotherapy	IV	March
brentuximab vedotin	Adcetris	Seagen	R/R large B-cell lymphoma in combination with lenalidomide and rituximab	IV	February
acalabrutinib	Calquence	AstraZeneca	Untreated mantle cell lymphoma in combination with bendamustine and rituximab	Oral	January
fam-trastuzumab deruxtecan-nxki	Enhertu	Daiichi Sankyo	Unresectable or metastatic HR+, HER2- (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer	IV	January
panitumumab	Vectibix	Amgen	KRAS G12C-mutated metastatic colorectal cancer in combination with sotorasib	IV	January
sotorasib	Lumakras	Amgen	KRAS G12C-mutated metastatic colorectal cancer in combination with panitumumab	Oral	January

Generic name	Brand name	Manufacturer	Indication(s)	Route of administration	Month approved*
amoxicillin and clavulanate†	Augmentin XR	USAntibiotics	(1) Community acquired pneumonia; (2) Acute bacterial sinusitis	Oral	December
etripamil	Cardamyst	Milestone	Paroxysmal supraventricular tachycardia	Intranasal	December
lerodalcibep-liga	Lerochol	LIB	LDL-C reduction in hypercholesterolemia, including HeFH	SC	December
semaglutide oral tablets	Wegovy	Novo Nordisk	Patients with obesity or overweight for (1) weight management and (2) MACE risk reduction in established CVD	Oral	December
sildenafil oral film	Vybrique	IBSA	Erectile dysfunction	Oral	December
tradipitant	Nereus	Vanda	Motion sickness	Oral	December
zoliflodacin	Nuzolvence	Entasis	Uncomplicated gonorrhea (≥ 12 years of age weighing ≥ 35 kg)	Oral	December
clonidine oral solution	Javadin	Azurity	HTN	Oral	October
elinzanetant	Lynkuet	Bayer	Vasomotor symptoms due to menopause	Oral	October
fosfomycin	Contepo	Meitheal	Complicated UTI	IV	October
furosemide	Lasix Onyu	SQ Innovation	Edema associated with CHF	SC (infusor system)	October
bimatoprost ophthalmic gel	Zolymbus	Thea	Reduction of intraocular pressure in open-angle glaucoma or ocular hypertension	Ophthalmic	September
bumetanide nasal spray	Enbumyst	Corstasis	Edema associated with CHF, hepatic and renal disease	Intranasal	September
clotrimazole otic solution	Clotic	Carwin	Fungal otitis externa due to Aspergillus and Candida species	Otic	September
lamotrigine oral suspension	Subvenite	OWP	(1) Adjunctive therapy for epilepsy (≥ 2 years of age); (2) Monotherapy for epilepsy (≥ 16 years of age); (3) Bipolar I disorder	Oral	September
lidocaine topical system	Bondlido	MedRx	Post-herpetic neuralgia	Topical	September
cyclobenzaprine sublingual tablets	Tonmya	Tonix	Fibromyalgia	Oral	August
escitalopram capsules	no trade name	Almatica	(1) Major depressive disorder (12 to < 65 years of age); (2) Generalized anxiety disorder (adults < 65 years of age)	Oral	August
aceclidine ophthalmic solution	Vizz	Lenz	Presbyopia	Ophthalmic	July
amlodipine oral solution	Sdamlo	Brillian	(1) HTN (≥ 6 years of age); (2) Risk reduction in CAD	Oral	July
celecoxib oral suspension	Vyscoxa	Carwin	(1) Osteoarthritis; (2) Rheumatoid arthritis (RA); (3) Ankylosing spondylitis; (4) Juvenile RA (≥ 2 years of age)	Oral	July
delgocitinib	Anzupgo	Leo	Chronic hand eczema	Topical	July
methocarbamol oral suspension	Atmeksi	Metacel/ Rosemont	Acute painful musculoskeletal conditions (≥ 16 years of age)	Oral	July
ramipril oral solution	Vostally	Metacel/ Rosemont	(1) HTN; (2) Risk reduction in patients ≥ 55 years of age at high risk for MACE; (3) Risk reduction in post-MI HF	Oral	July
lisdexamfetamine dimesylate oral solution	Arynta	Azurity	(1) ADHD (≥ 6 years of age); (2) Binge eating disorder	Oral	June
telmisartan/ amlodipine/ indapamide	Widaplik	George Medicines	HTN	Oral	June
acoltremon	Tryptyr	Alcon	Dry eye disease	Ophthalmic	May
dihydroergotamine injection	Brekiya	Amneal	Acute treatment of migraine and cluster headaches	SC	May
aripiprazole oral film	Mezofy	CMG	Schizophrenia (≥ 13 years of age)	Oral	April
dihydroergotamine nasal powder	Atzumi	Satsuma	Acute treatment of migraine	Intranasal	April
metoprolol tartrate oral solution	Lopressor	Validus	(1) HTN; (2) Long-term treatment of angina pectoris; (3) Hemodynamically stable patients with MI in conjunction with IV metoprolol	Oral	April
chlorthalidone	Hemiclor	PRM	HTN	Oral	March
gepotidacin	Blujepa	GSK	Uncomplicated UTI (females ≥ 12 years of age)	Oral	March
losartan oral suspension	Arbli	Scienture	(1) HTN (> 6 years of age); (2) Risk reduction in patients with HTN and LVH; (3) Diabetic nephropathy	Oral	March
aztreonam / avibactam	Emblaveo	Abbvie	Complicated intra-abdominal infections in combination with metronidazole	IV	February
copper intrauterine system	Miudella	Sebela Women's Health	Pregnancy prevention for up to 3 years	Intrauterine	February
hydrochlorothiazide oral suspension	Inzirqo	Ani	Adults and pediatric patients with (1) HTN; (2) Edema associated with CHF, hepatic cirrhosis and renal disease	Oral	January
meloxicam / rizatriptan	Symbravo	Axsome	Acute treatment of migraine	Oral	January
sitagliptin oral solution	Brynovin	Azurity	T2DM	Oral	January
suzetrigine	Journavx	Vertex	Moderate to severe acute pain	Oral	January

†Amoxicillin and clavulanate (Augmentin XR) is returning to the market under Commissioner's National Priority Voucher (CNPV) pilot program approval

Generic name	Brand name	Manufacturer	Indication(s)	Route of administration	Month approved*
cariprazine	Vraylar	Abbvie	(1) Indication for schizophrenia expanded to include patients ≥ 13 years of age; (2) Indication for acute treatment of bipolar I disorder expanded to include patients ≥ 10 years of age	Oral	December
cilastatin / imipenem / relebactam	Recarbrio	Merck Sharp and Dohme	Indications for complicated UTI, complicated intra-abdominal infections and HABP/VABP expanded to include pediatrics weighing ≥ 2 kg	IV	December
ferric maltol	Accrufer	Shield	Indication for iron deficiency expanded to include patients ≥ 10 years of age	Oral	December
flibanserin	Addyi	Sprout	Indication for generalized hypoactive sexual desire disorder expanded to include postmenopausal women < 65 years of age	Oral	December
furosemide	Furoscix	SC Pharmaceuticals	Indication for edema in chronic HF or CKD expanded to include pediatrics weighing ≥ 43 kg	SC (infusor system)	December
gepotidacin	Blujepa	GlaxoSmithKline	Uncomplicated gonorrhea (≥ 12 years of age weighing ≥ 45 kg)	Oral	December
tirzepatide	Mounjaro	Eli Lilly	Indication for T2DM expanded to include patients ≥ 10 years of age	SC	December
linaclotide	Linzess	Abbvie	Indication for IBS-C expanded to include patients ≥ 7 years of age	Oral	November
lumateperone	Caplyta	Intra-Cellular Therapies	Adjunctive therapy for major depressive disorder	Oral	November
naltrexone and bupropion	Contrave	Currax	Indication revised to remove BMI requirements	Oral	November
alirocumab	Praluent	Regeneron	Indication for MACE risk reduction expanded to include all adults at increased risk for MACE	SC	October
risperidone ER suspension	Uzedy	Teva	Bipolar I disorder	SC	October
roflumilast cream	Zoryve	Arcutis	Indication for atopic dermatitis expanded to include patients ≥ 2 years of age	Topical	October
semaglutide	Rybelsus	Novo Nordisk	MACE risk reduction in high-risk adults with T2DM	Oral	October
ruxolitinib	Opzelura	Incyte	Indication for atopic dermatitis expanded to include patients ≥ 2 years of age	Topical	September
evolocumab	Repatha	Amgen	Expanded indications: (1) MACE risk reduction in patients at increased risk; (2) monotherapy for HeFH and HoFH	SC	August
fremanezumab-vfrm	Ajovy	Teva	Episodic migraine prevention in patients 6 to 17 years of age weighing ≥ 45 kg	SC	August
semaglutide	Wegovy	Novo Nordisk	Noncirrhotic MASH with F2 to F3 fibrosis	SC	August
bictegravir/ emtricitabine/ tenofovir alafenamide	Biktarvy	Gilead	Complete regimen for HIV-1 (adults and pediatrics weighing ≥ 14 kg)	Oral	July
finerenone	Kerendia	Bayer	Risk reduction in HF with LVEF ≥ 40%	Oral	July
cobicistat	Tybost	Gilead	Indication for HIV-1 expanded to include: (1) pediatric patients weighing ≥ 14 kg to < 35 kg in combination with atazanavir and other ARVs except for tenofovir alafenamide; (2) pediatric patients weighing ≥ 15 kg to < 40 kg in combination with darunavir and other ARVs	Oral	June
emtricitabine/ tenofovir alafenamide fumarate	Descovy	Gilead	Indication for HIV-1 expanded to include pediatric patients weighing ≥ 14 kg to < 35 kg in combination with other ARVs, including darunavir and cobicistat, but not other protease inhibitors that require a CYP3A inhibitor	Oral	June
roflumilast 0.3% foam	Zoryve	Arcutis	Plaque psoriasis of the scalp and body (≥ 12 years of age)	Topical	May
apixaban	Eliquis	Bristol-Myers Squibb	Indication for treatment of VTE and risk reduction for recurrent VTE expanded to include pediatric patients from birth	Oral	April
dexamethasone ophthalmic insert	Dextenza	Ocular Therapeutix	Indications expanded to include pediatric patients: (1) ocular inflammation and pain following ophthalmic surgery; (2) allergic conjunctivitis (≥ 2 years of age)	Ophthalmic insert	April
diazepam nasal spray	Valtoco	Neurelis	Indication expanded to include pediatric patients ≥ 2 years of age with epilepsy	Intranasal	April
palonosetron	Posfrea	Avyxa	Indication for chemotherapy-induced nausea and vomiting expanded to include patients 1 month to < 17 years of age	IV	April
tedizolid	Sivextro	Cubist	Indication for ABSSSI expanded to include (1) patients < 12 years of age weighing ≥ 35 kg (oral); (2) patients ≥ 26 weeks gestational age and weighing ≥ 1 kg (IV)	IV, Oral	April
darunavir / cobicistat	Prezcobix	Janssen	Expanded indication (≥ 25 kg to < 40 kg) for HIV-1 infection	Oral	March
epinephrine nasal spray	Neffy	ARS	Expanded indication (≥ 4 years of age weighing ≥ 15 kg) for type I allergic reactions	Intranasal	March
glucagon nasal powder	Baqsimi	Amphastar	Expanded indication (1 to 3 years of age) for severe hypoglycemia	Intranasal	March
emtricitabine / rilpivirine / tenofovir alafenamide	Odefsey	Gilead	Expanded indication (≥ 25 kg to < 35 kg) for HIV-1 infection	Oral	February
house dust mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus) allergen extract	Odactra	ALK-Abello	Expanded indication (5 to 11 years of age) for house dust mite-induced allergic rhinitis	Oral	February
moxidectin	no trade name	Medicines Development for Global Health	Expanded indication (4 to < 12 years of age) for onchocerciasis	Oral	February
semaglutide	Ozempic	Novo Nordisk	Reduce risk of worsening kidney disease and CV death in patients with T2DM and CKD	SC	January

Generic name	Brand name	Manufacturer	Indication(s)	Route of administration	Month approved*
COVID-19 vaccine, mRNA	Spikevax	Moderna	Full approval for COVID-19 prevention in patients 6 months to 64 years of age who are at increased risk	IM	July
COVID-19 vaccine, adjuvanted	Nuvaxovid	Novavax	Active immunization to prevent COVID-19 in: (1) adults ≥ 65 years of age; (2) high-risk patients 12 to 64 years of age	IM	May
COVID-19 vaccine, mRNA	mNexspike	Moderna	Active immunization to prevent COVID-19 in: (1) adults ≥ 65 years of age; (2) high-risk patients 12 to 64 years of age	IM	May
smallpox and mpox vaccine, live, non-replicating, freeze-dried formulation	Jynneos	Bavarian Nordic	Prevention of smallpox and mpox disease	IM	March
chikungunya vaccine, recombinant	Vimkunya	Bavarian Nordic	Prevention of chikungunya virus disease (≥ 12 years of age)	IM	February
meningococcal groups A, B, C, W and Y vaccine	Penmenvy	GSK	Prevention of disease caused by Neisseria meningitidis serogroups A, B, C, W and Y (10 through 25 years of age)	IM	February

Generic name	Brand name	Manufacturer	Indication(s)	Route of administration	Month approved*
RSV vaccine	mResvia	Moderna	Indication for prevention of LRTD caused by RSV expanded to include patients 18 through 59 years of age who are at increased risk	IM	June
meningococcal (groups A, C, Y, W) conjugate vaccine	MenQuadfi	Sanofi Pasteur	Indication for prevention of invasive meningococcal disease expanded to include patients 6 weeks to 23 months of age	IM	May

Generic name	Brand name	Reference product	Manufacturer	Indication(s)	Route of administration	Month approved*
denosumab-mobz	Boncresa (interchangeable)	Prolia	Amneal	Bone health	SC	December
denosumab-mobz	Oziltus (interchangeable)	Xgeva	Amneal	Bone health	SC	December
ranibizumab-leyk	Nufymco (interchangeable)	Lucentis	Formycon	Macular and retinal disorders	Intravitreal	December
pegfilgrastim-unne	Armlupeg	Neulasta	Lupin	Neutropenia	SC	November
pertuzumab-dpzb	Poherdy (interchangeable)	Perjeta	Organon	Breast cancer	IV	November
aflibercept-boav	Eydenzelt	Eylea	Celltrion	Macular and retinal disorders	Intravitreal	October
denosumab-desu	Jubereq (interchangeable)	Xgeva	Accord	Bone health	SC	October
denosumab-desu	Osvyrti (interchangeable)	Prolia	Accord	Bone health	SC	October
denosumab-kyqq	Aukelso (provisional interchangeability)	Xgeva	Biocon	Bone health	SC	September
denosumab-kyqq	Bosaya (provisional interchangeability)	Prolia	Biocon	Bone health	SC	September
denosumab-qbde	Enoby	Prolia	Gedeon/ Hikma	Bone health	SC	September
denosumab-qbde	Xtrenbo	Xgeva	Gedeon/ Hikma	Bone health	SC	September
denosumab-nxxp	Bildyos	Prolia	Organon	Bone health	SC	August
denosumab-nxxp	Bilprevda	Xgeva	Organon	Bone health	SC	August
insulin aspart-xjhz	Kirsty (interchangeable)	Novolog	Biocon	Diabetes mellitus (adults and pediatrics)	IV, SC	July
ustekinumab-hmny	Starjemza (interchangeable)	Stelara	Bio-Thera/Hikma	Autoimmune disorders	IV, SC	May
bevacizumab-nwgd	Jobevne	Avastin	Biocon	Select patients with CRC, NSCLC, glioblastoma, RCC, cervical cancer and epithelial ovarian, fallopian tube or primary peritoneal cancer	IV	April
denosumab-bnht	Bomyntra	Xgeva	Fresenius Kabi	Bone health	SC	March
denosumab-bnht	Conexxence	Prolia	Fresenius Kabi	Bone health	SC	March
omalizumab-igec	Omlyclo (interchangeable)	Xolair	Celltrion	(1) Asthma; (2) Chronic rhinosinusitis with nasal polyps; (3) IgE-mediated food allergies; (4) Chronic spontaneous urticaria	SC	March
denosumab-bmwo	Osenvelt	Xgeva	Celltrion	Bone health	SC	February
denosumab-bmwo	Stoboclo	Prolia	Celltrion	Bone health	SC	February
denosumab-dssb	Ospomyv	Prolia	Samsung Bioepis	Bone health	SC	February
denosumab-dssb	Xbryk	Xgeva	Samsung Bioepis	Bone health	SC	February
insulin aspart-szjj	Merilog, Merilog SoloStar	Novolog	Sanofi-Aventis	Diabetes mellitus	SC	February
tocilizumab-anoh	Avtozma	Actemra	Celltrion	Autoimmune disorders and COVID-19	IV, SC	January

Generic name	Brand name	Manufacturer	Indication(s)	Route of administration	Month approved*
adalimumab-aacf	Idacio	Fresenius Kabi	(1) Uveitis (≥ 2 years of age); (2) Hidradenitis suppurativa (≥ 12 years of age)	SC	December
adalimumab-aaty	Yuflyma (interchangeable)	Celltrion	(1) Uveitis (≥ 2 years of age); (2) Hidradenitis suppurativa (≥ 12 years of age)	SC	October
adalimumab-adaz	Hyrimoz (interchangeable)	Sandoz	(1) Uveitis (≥ 2 years of age); (2) Hidradenitis suppurativa (≥ 12 years of age)	SC	October
adalimumab-adbm	Cyltezo (interchangeable)	Boehringer Ingelheim	(1) Uveitis (≥ 2 years of age); (2) Hidradenitis suppurativa (≥ 12 years of age)	SC	October
adalimumab-atto	Amjevita (interchangeable)	Amgen	(1) Uveitis (≥ 2 years of age); (2) Hidradenitis suppurativa (≥ 12 years of age)	SC	October
adalimumab-ryvk	Simlandi (interchangeable)	Alvotech	(1) Uveitis (≥ 2 years of age); (2) Hidradenitis suppurativa (≥ 12 years of age)	SC	October
tocilizumab-anoh	Avtozma (interchangeable)	Celltrion	CAR T cell-induced CRS (≥ 2 years of age)	IV	July
rituximab-abbs	Truxima	Teva	Pemphigus vulgaris	IV	June
rituximab-arrx	Riabni	Amgen	Pemphigus vulgaris	IV	June
rituximab-pvvr	Ruxience	Pfizer	Pemphigus vulgaris	IV	June
filgrastim-ayow	Releuko	Kashiv Biosciences	(1) Autologous hematopoietic progenitor cell mobilization for leukapheresis collection; (2) Hematopoietic syndrome of acute radiation syndrome	SC	April
pegfilgrastim-pbbk	Fylnetra	Kashiv Biosciences	Hematopoietic subsyndrome of acute radiation syndrome	SC	April
tocilizumab-aazg	Tyenne	Fresenius Kabi	(1) Hospitalized adults with COVID-19; (2) CAR T cell-induced CRS (≥ 2 years of age)	IV	February

Generic name	Brand name	Manufacturer	Indication(s)	Route of administration	Month approved*
etuvetidigene autotemcel	Waskyra	Fondazione Telethon	Wiskott-Aldrich syndrome (≥ 6 months of age)	IV	December
onasemnogene abeparvovec-brve	Itvisma	Novartis	Spinal muscular atrophy with SMN1 gene mutation (≥ 2 years of age)	Intrathecal	November
zopapogene imadenovec-drba	Papzimeos	Precigen	Recurrent respiratory papillomatosis	SC	August
prademagene zamikeracel	Zevaskyn	Abeona	Recessive dystrophic epidermolysis bullosa	Surgical - Topical	April
revakinagene taroretcel-lwey	Encelto	Neurotech	Macular telangiectasia type 2	Intravitreal	March

Generic name	Brand name	Manufacturer	Indication(s)	Route of administration	Month approved*
lisocabtagene maraleucel	Breyanzi	Bristol-Myers Squibb	R/R marginal zone lymphoma	IV	December
omidubicel-onlv	Omisirge	Gamida Cell	Severe aplastic anemia (≥ 6 years of age)	IV	December
beremagene geperpavec-svdt	Vyjuvek	Krystal	Indication for dystrophic epidermolysis bullosa expanded to include pediatrics from birth	Topical	September

AAVRh74var adeno-associated virus serotype Rh74var
ABSSSI acute bacterial skin and skin structure infections
AChR acetylcholine receptor
ADHD attention deficit hyperactivity disorder
ALK anaplastic lymphoma kinase
ALK+ anaplastic lymphoma kinase-positive
ALL acute lymphoblastic leukemia
AML acute myeloid leukemia
AQP4 anti-aquaporin-4
ARV antiretroviral
ASPS alveolar soft part sarcoma
BCG Bacillus Calmette-Guérin
BMI body mass index
BPH benign prostatic hyperplasia
BRAF v-raf murine sarcoma viral oncogene homolog B1
BRCA2 breast cancer gene 2
BTC biliary tract cancer
BTK Bruton tyrosine kinase
CAD coronary artery disease
CAR chimeric antigen receptor
CD19+ cluster of differentiate 19-positive
CD22+ cluster of differentiate 22-positive
CFTR cystic fibrosis transmembrane conductance regulator
CHF congestive heart failure
CIDP chronic inflammatory demyelinating polyneuropathy
CIS carcinoma in situ
CKD chronic kidney disease
CLL chronic lymphocytic leukemia
CML chronic myeloid leukemia
COPD chronic obstructive pulmonary disease
COVID-19 coronavirus disease 2019
CRC colorectal cancer
CRS cytokine release syndrome
CSCC cutaneous squamous cell carcinoma
CV cardiovascular
CVD cardiovascular disease
CYP cytochrome P450
DMD Duchenne muscular dystrophy
dMMR deficient mismatch repair
EGFR epidermal growth factor receptor
ER extended release
ER+ estrogen receptor-positive
ERBB2 erythroblastic oncogene B receptor 2
ERC enhanced removal capability
ESR1 estrogen receptor 1
FGFR3 fibroblast growth factor receptor 3
FLOT fluorouracil, leucovorin, oxaliplatin and docetaxel
GERD gastroesophageal reflux disease
GEJ gastroesophageal junction
GVHD graft versus host disease
HABP hospital-acquired bacterial pneumonia
HCC hepatocellular carcinoma
HCI hydrochloride
HeFH heterozygous familial hypercholesterolemia
HER2 human epidermal growth factor receptor 2
HER2+ human epidermal growth factor receptor 2-positive
HER2- human epidermal growth factor receptor 2-negative
HF heart failure
HIV-1 human immunodeficiency virus type-1
HNSCC head and neck squamous cell cancer
HoFH homozygous familial hypercholesterolemia
HR hormone receptor
HR+ hormone receptor-positive
HSCT hematopoietic stem cell transplant
HTN hypertension
IBS-C irritable bowel syndrome with constipation
IDH isocitrate dehydrogenase
Ig immunoglobulin
IHC immunohistochemistry
IM intramuscular
IR Immediate-release
ISH in situ hybridization
IV intravenous
KMT2A lysine methyltransferase 2A gene
KRAS Kirsten rat sarcoma virus
LDL-C low-density lipoprotein cholesterol
LEPR leptin receptor
LRTD lower respiratory tract disease
LVEF left ventricular ejection fraction
LVH left ventricular hypertrophy
MACE major adverse cardiovascular events
MASH metabolic dysfunction-associated steatohepatitis
MCC Merkel cell carcinoma
MDS myelodysplastic syndrome
mFOLFOX6 fluorouracil, leucovorin, oxaliplatin
MI myocardial infarction
MPM malignant pleural mesothelioma
MSI-H microsatellite instability-high
MuSK muscle-specific tyrosine kinase
NPM1 nucleophosmin 1
NRG1+ neuregulin 1-positive
NSCLC non-small cell lung cancer
NTRK neurotrophic tyrosine receptor kinase
ODT orally disintegrating tablet
PAH pulmonary arterial hypertension
PCSK1 proprotein convertase subtilisin/kexin type 1
PD-L1+ programmed death-ligand 1-positive
Ph+ Philadelphia chromosome-positive
Ph- Philadelphia chromosome-negative
PIK3CA phosphatidylinositol-3-kinase catalytic subunit alpha
POMC pro-opiomelanocortin
PrEP pre-exposure prophylaxis
PsA psoriatic arthritis
PsO plaque psoriasis
R/R relapsed or refractory
RCC renal cell carcinoma
RET rearranged during transfection
RNA ribonucleic acid
RSV respiratory syncytial virus
RVO retinal vein occlusion
SC subcutaneous
SCLC small cell lung cancer
sJIA systemic juvenile idiopathic arthritis
SLL small lymphocytic leukemia
SMN1 survival motor neuron 1
T2DM type 2 diabetes mellitus
TMB-H tumor mutational burden-high
TNBC triple-negative breast cancer
TKD tyrosine kinase domain
UTI urinary tract infection
VABP ventilator-associated bacterial pneumonia
VEGF vascular endothelial growth factor
VTE venous thromboembolism
XR extended release

About us

Corporate social responsibility

Solutions overview

Modern technology

Drug access

Clinical solutions

Condition management

Specialty drug management

Government solutions

Single-state programs

Read

Watch

Listen

Home Delivery

Specialty Pharmacy

Navigate to

Back

Back

Back

Back

Specialty drug approvals

Traditional drug approvals

Cellular and gene therapy and biosimilar approvals

Login Portals

Compliance / Legal

Company